Clinical Trials Directory

Trials / Completed

CompletedNCT01256060

Intranasal Oxytocin for the Treatment of Children and Adolescents With ASD (OXY)

Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Evdokia Anagnostou · Individual
Sex
All
Age
10 Years – 17 Years
Healthy volunteers
Not accepted

Summary

Extensive data has been accumulated to suggest that central release of oxytocin is important for social cognition and function, as well as likely involved in anxiety modulation and repetitive behaviors. The principal investigators of this study have previously documented: 1) an association between Autism Spectrum Disorder and a single nuclear polymorphism of the oxytocin receptor gene, 2) ability to measure oxytocin levels in the blood by enzyme immunoassay and 3) preliminary data to support safety and efficacy of intranasal oxytocin in the treatment of social deficits and repetitive behaviors in adults with autism. A medication treatment targeting the core deficits of Autism Spectrum Disorder in childhood is highly valuable because it could influence the developmental trajectory and make further psychosocial interventions possible. In this context, we propose a small dose finding study to confirm that the dose used in the adult study is not more than the maximum tolerated dose in youth. '

Conditions

Interventions

TypeNameDescription
DRUGIntranasal OxytocinWe are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.

Timeline

Start date
2010-11-01
Primary completion
2013-03-01
Completion
2013-03-01
First posted
2010-12-08
Last updated
2016-08-12
Results posted
2015-04-15

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01256060. Inclusion in this directory is not an endorsement.